The 20 Best Orchiectomy Doctors Near Me

Find the Experts and Specialists who perform Orchiectomy

OverviewFind a DoctorLatest AdvancesClinical Trials
Joshua J. Meeks
Distinguished in Orchiectomy

Dr. Joshua J. Meeks

Oncology
Northwestern Medical Group
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
21 Years of Experience
Distinguished in Orchiectomy
Northwestern Medical Group
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua Meeks is an Oncologist in Chicago, Illinois. Dr. Meeks has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in Orchiectomy. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Reconstructive Urology Surgery.

His clinical research consists of co-authoring 165 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Orchiectomy.

Graduate Institution
Northwestern University Feinberg School Of Medicine, 2005.0
Specialties
Oncology
Licenses
Urology in IL
Board Certifications
American Board Of Urology - Urology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Northwestern Medicine Mchenry
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

675 N St Clair St Ste 20-150, Galter Pavilion, Chicago, IL 60611
Call: 312-695-8146

Additional Areas of Focus

Dr. Meeks has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Bladder Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Other, Dietary supplement
Study Phase: Phase 3
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Biological, Other
Study Drugs: Engineered Oncolytic Adenovirus, Pembrolizumab, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 2
A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Pembrolizumab
Study Phase: Phase 1
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Enrollment Status: Terminated
Publish Date: May 01, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

165 Total Publications

Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?
Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?
Journal: European urology focus
Published: November 07, 2025
View All 165 Publications
Similar Doctors
Advanced in Orchiectomy
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology
Advanced in Orchiectomy
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology

City Of Hope Medical Group Of Illinois PLLC

2520 Elisha Ave, 
Zion, IL 
 (39.7 miles away)
847-872-4561
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients

Walter Stadler is a Hematologist Oncology specialist and a Hematologist in Zion, Illinois. Dr. Stadler is rated as an Elite provider by MediFind in Orchiectomy. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Orchiectomy, and Nephrectomy. Dr. Stadler is currently accepting new patients.

Hiten D. Patel
Advanced in Orchiectomy
Dr. Hiten D. Patel
Oncology
Advanced in Orchiectomy
Dr. Hiten D. Patel
Oncology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
312-695-8146
Experience:
12+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hiten Patel is an Oncologist in Chicago, Illinois. Dr. Patel has been practicing medicine for over 12 years and is rated as a Distinguished provider by MediFind in Orchiectomy. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Testicular Cancer, Nephrectomy, and Prostatectomy.

David Vanderweele
Experienced in Orchiectomy
Dr. David Vanderweele
Hematology | Oncology
Experienced in Orchiectomy
Dr. David Vanderweele
Hematology | Oncology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
866-587-4322
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Vanderweele is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Vanderweele has been practicing medicine for over 19 years and is rated as a Distinguished provider by MediFind in Orchiectomy. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Orchiectomy, and Prostatectomy.

VIEW MORE ORCHIECTOMY DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meeks's expertise for a condition
ConditionClose
  • Elite
  • Bladder Cancer
    Dr. Meeks is
    Elite
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Muscle Invasive Bladder Cancer
    Dr. Meeks is
    Elite
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Meeks is
    Elite
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Urothelial Cancer
    Dr. Meeks is
    Elite
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
  • Distinguished
  • Familial Prostate Cancer
    Dr. Meeks is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Orchiectomy
    Dr. Meeks is
    Distinguished
    . Learn about Orchiectomy.
    See more Orchiectomy experts
  • Prostate Cancer
    Dr. Meeks is
    Distinguished
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Reconstructive Urology Surgery
    Dr. Meeks is
    Distinguished
    . Learn about Reconstructive Urology Surgery.
    See more Reconstructive Urology Surgery experts
  • Renal Cell Carcinoma (RCC)
    Dr. Meeks is
    Distinguished
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Advanced
  • Adult Soft Tissue Sarcoma
    Dr. Meeks is
    Advanced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Meeks is
    Advanced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Meeks is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Meeks is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Nephrectomy
    Dr. Meeks is
    Advanced
    . Learn about Nephrectomy.
    See more Nephrectomy experts
  • Penile Cancer
    Dr. Meeks is
    Advanced
    . Learn about Penile Cancer.
    See more Penile Cancer experts
View All 11 Advanced Conditions
  • Experienced
  • Bladder Reconstruction
    Dr. Meeks is
    Experienced
    . Learn about Bladder Reconstruction.
    See more Bladder Reconstruction experts
  • Endoscopy
    Dr. Meeks is
    Experienced
    . Learn about Endoscopy.
    See more Endoscopy experts
  • Mesothelioma
    Dr. Meeks is
    Experienced
    . Learn about Mesothelioma.
    See more Mesothelioma experts
  • Metastatic Pleural Tumor
    Dr. Meeks is
    Experienced
    . Learn about Metastatic Pleural Tumor.
    See more Metastatic Pleural Tumor experts
  • Neuroendocrine Tumor
    Dr. Meeks is
    Experienced
    . Learn about Neuroendocrine Tumor.
    See more Neuroendocrine Tumor experts
  • Retinoblastoma
    Dr. Meeks is
    Experienced
    . Learn about Retinoblastoma.
    See more Retinoblastoma experts
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Close
      0 / 1000

      Please provide us with the below insurance information:

              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.